Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort

BACKGROUND: Optimization of treatment with biologics is currently an unmet need for patients with ulcerative colitis (UC). Real-world studies provide neutral estimates of drug efficacy and safety within unselected patient populations and allow for the recognition of specific characteristics that aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Bamias, Giorgos, Kokkotis, Georgios, Gizis, Michalis, Kapizioni, Christina, Karmiris, Konstantinos, Koureta, Evgenia, Kyriakos, Nikolaos, Leonidakis, Georgios, Makris, Konstantinos, Markopoulos, Panagiotis, Michalopoulos, Georgios, Michopoulos, Spyridon, Papaconstantinou, Ioannis, Polymeros, Dimitrios, Siakavellas, Spyros I., Triantafyllou, Konstantinos, Tsironi, Eftychia, Tsoukali, Emmanouela, Tzouvala, Maria, Viazis, Nikos, Xourafas, Vassileios, Zacharopoulou, Eirini, Zampeli, Evanthia, Zografos, Konstantinos, Papatheodoridis, George, Mantzaris, Gerasimos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942521/
https://www.ncbi.nlm.nih.gov/pubmed/33751325
http://dx.doi.org/10.1007/s10620-021-06907-5
Descripción
Sumario:BACKGROUND: Optimization of treatment with biologics is currently an unmet need for patients with ulcerative colitis (UC). Real-world studies provide neutral estimates of drug efficacy and safety within unselected patient populations and allow for the recognition of specific characteristics that affect response to therapy. AIMS: We aimed to depict the efficacy of vedolizumab in patients with UC in a real-world setting and identify prognosticators of improved outcomes. METHODS: Patients with active UC who commenced treatment with vedolizumab were prospectively followed up. Patient-reported outcomes (PROs) and clinical/endoscopic-reported outcomes were recorded at baseline and at weeks 14 and 54. Predefined endpoints of early and persistent efficacy were analyzed against clinical characteristics to identify prognostic factors for response. RESULTS: We included 96 patients (anti-TNF-exposed = 38.5%). At week 14, 73 patients (76%) had clinical response and 54 (56.3%) clinical remission. At week 54, the primary endpoint of vedolizumab persistence was met by 72 patients (75%), whereas steroid-free clinical remission by 59.4%. Among patients who had endoscopy, rates for mucosal healing (Mayo endoscopic score of 0) were 29.8% at week 14 and 44.6% at week 54, respectively. Vedolizumab treatment led to significant improvements in quality of life. Corticosteroid-refractory or anti-TNF-refractory disease, articular manifestations, and high baseline UC-PRO2 were associated with decreased efficacy of vedolizumab in the primary and secondary outcomes. CONCLUSIONS: Vedolizumab is characterized by high efficacy and long-term treatment persistence in UC. More aggressive disease, as indicated by refractoriness to steroids or anti-TNFs and elevated baseline PROs, may predict suboptimal response and help pre-treatment prognostic stratification of patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10620-021-06907-5.

Ejemplares similares